Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database
文献类型：期刊论文
| 作者 | Guisen Yin3; Guiling Song3; Shuyi Xue1; Fen Liu2 |
| 刊名 | SCIENTIFIC REPORTS
 |
| 卷号 | 14期号:1 |
| ISSN号 | 2045-2322 |
| 英文摘要 | Fulvestrant, as the first selective estrogen receptor degrader, is widely used in the endocrine treatment of breast cancer. However, in the real world, there is a lack of relevant reports on adverse reaction data mining for fulvestrant. To perform data mining on adverse events (AEs) associated with fulvestrant and explore the risk factors contributing to severe AEs, providing a reference for the rational use of fulvestrant in clinical practice. Retrieved adverse event report information associated with fulvestrant from the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database, covering the period from market introduction to September 30, 2023. Suspicious AEs were screened using the reporting odds ratio (ROR) and proportional reporting ratio methods based on disproportionality analysis. Univariate and multivariate logistic regression analyses were conducted on severe AEs to explore the risk factors associated with fulvestrant-induced severe AEs. A total of 6947 reports related to AEs associated with fulvestrant were obtained, including 5924 reports of severe AEs and 1023 reports of non-severe AEs. Using the disproportionality analysis method, a total of 210 valid AEs were identified for fulvestrant, with 45 AEs (21.43%) not listed in the product labeling, involving 11 systems and organs. The AEs associated with fulvestrant were sorted by frequency of occurrence, with neutropenia (325 cases) having the highest number of reports. By signal strength, injection site pruritus showed the strongest signal (ROR?=?658.43). The results of the logistic regression analysis showed that concurrent use of medications with extremely high protein binding (≥?98%) is an independent risk factor for severe AEs associated with fulvestrant. Age served as a protective factor for fulvestrant-related AEs. The co-administration of fulvestrant with CYP3A4 enzyme inhibitors did not show statistically significant correlation with the occurrence of severe AEs. Co-administration of drugs with extremely high protein binding (≥?98%) may increase the risk of severe adverse reactions of fulvestrant. Meanwhile, age (60–74years) may reduce the risk of severe AEs of fulvestrant. However, further clinical research is still needed to explore and verify whether there is interaction between fulvestrant and drugs with high protein binding through more clinical studies. |
| 语种 | 英语 |
| 源URL | [http://ir.yic.ac.cn/handle/133337/42113]  |
| 专题 | 烟台海岸带研究所_中科院烟台海岸带研究所知识产出 |
| 作者单位 | 1.University of Health and Rehabilitation Sciences 2.Central South University/Hunan Cancer Hospital 3.中国科学院烟台海岸带研究所 |
| 推荐引用方式 GB/T 7714 | Guisen Yin,Guiling Song,Shuyi Xue,et al. Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database[J]. SCIENTIFIC REPORTS,14(1). |
| APA | Guisen Yin,Guiling Song,Shuyi Xue,&Fen Liu. |
| MLA | Guisen Yin,et al."Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database".SCIENTIFIC REPORTS 14.1 |
入库方式： OAI收割
来源：烟台海岸带研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。